California-based gene editing biotechnology company Metagenomi has raised an additional USD 100 million in a Series B extension.This round was co-led by Novo Holdings A/S, Catalio Capital Management, and SymBiosis, with participation from new and existing investors, including Leaps by Bayer and Moderna, bringing the total funds raised by the company to USD 457 million. Furthermore, Novo Ventures’ Partner Ray Camahort will join the company’s board of directors as an observer.
The new funds will be used to advance its lead programs through preclinical developments and into clinical proof-of-concept studies. Furthermore, the company plans to expand its targets for preclinical proof-of-concept studies using its proprietary discovery engine.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.